The number of patients registered for the study was low and it was expected to be difficult to derive the study results.

Comparatively analyze the safety and validity of Amplazter Cardiac Plug (ACP) device-using percutaneous left atrial appendage closure, and the medical treatment with dabigatran plus aspirin or dabigatran plus clopidogrel after 3months triple therapy (Dabigatran plus DAPT (dual-antiplatelet therapy)) in patient with coronary artery disease treated with drug-eluting stent, accompanying atrial fibrillation.

Total of 670 patients [left atrial appendage occlusion registry with 100 ACP/ 570 anti-coagulation registry: (285 Dabigatran plus aspirin) and (285 Dabigatran plus clopidogrel) therapy)] will be comparatively analyzed the safety and efficacy. Primary endpoints were a composite of death, non-fatal myocardial infarction, stroke, systemic embolism, and GUSTO bleeding (moderate to severe).

Inclusion Criteria:

1. Patients older than 20 years accompanying chronic atrial fibrillation with CHADS2 score ≥2
2. Patients with coronary artery disease (which requires DES) should receive the 2nd generation drug-eluting stent insertion treatment
3. Subjects and their legal representatives must understand the main purpose of this study, agree with relevant provisions, and sign to consent forms approved by IRBs of each institution.
4. Subjects should agree with the follow-up studies as (coronary angiography) and transesophageal echocardiography, etc.
5. Subjects should agree to follow our requests for post-operative follow-up visits.

Exclusion Criteria:

1. Patients showing any hypersensitive reaction or reason for restriction to aspirin, heparin, clopidogrel, or warfarin, or otherwise, susceptible to contrast media, and therefore, who could not use those drugs and who were pregnant or breast feeding.
2. Comorbidities other than atrial fibrillation that required chronic warfarin use.
3. Patients diagnosed with progressive infection condition or endocarditis.
4. Patients who have been diagnosed with progressive gastric ulcer or upper gastrointestinal bleeding for last 3 months.
5. Hemodynamically unstable patients who needs inotropic supports.
6. Senile dementia patients who have experienced any cerebrovascular accident (CVA) for last 6 weeks.
7. Patients who have been diagnosed with intracardiac mass, thrombus, or vegetation as echocardiographic findings.
8. Patients diagnosed with severe left ventricular dysfunction (\